Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...

Considering taking supplements to treat prurigo nodularis? Below is a list of common natural remedies used to treat or reduce the symptoms of prurigo nodularis. Follow the links to read common ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. Dupixent nears EU approval for rare ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

IL-31 is a protein that drives itch and plays a role in inflammation and skin barrier dysfunction in both AD and prurigo nodularis and fibrosis in prurigo nodularis, the company states.

Nemluvio’s approved indications include atopic dermatitis in patients aged 12 years and older and prurigo nodularis in adults. The approvals are supported by two phase 3 clinical trial programs.

The European Commission (EC) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The drug has been authorised for use in atopic dermatitis patients ...